Biohit Oyj, Stock Exchange Release, December 16, 2015 at 3:30 pm. local time (EET)
Biohit Oyj’s Board of Directors has decided to distribute in total 60,000 option rights in class I 2013C of the option scheme I 2013 to the members of the company’s management team excluding the CEO as follows: Hendolin Panu 15,000 pcs, Nordström Niklas 15,000 pcs, Mickels Anu 15,000 pcs and Astola Annika, 15,000 pcs.
Each option right entitles its holder to subscribe for one (1) of the company’s new class B-shares. Share subscription price is 2.2766 euros. The subscription price can be amended pursuant to the terms and conditions of the option scheme.
Additional information:
CEO Semi Korpela, Biohit Oyj
tel. +358 9 773 861
investor.relations@biohit.fi
www.biohithealthcare.com
Biohit in brief
Biohit Oyj is a globally operating Finnish biotechnology company. Biohit’s mission is “Innovating for Health” – we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit's Series B share (BIOBV) is quoted on Nasdaq Helsinki in the Small cap/Healthcare group. www.biohithealthcare.com